{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:56:20Z","timestamp":1793134580052,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s12020-020-02425-y","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T19:02:46Z","timestamp":1596049366000},"page":"427-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer"],"prefix":"10.1007","volume":"71","author":[{"given":"Mijin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonghwa","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Eun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Cheol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Jun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Kee","family":"Shong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ji","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"issue":"11","key":"2425_CR1","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrendo.2017.76","volume":"13","author":"E Molinaro","year":"2017","unstructured":"E. Molinaro, C. Romei, A. Biagini, E. Sabini, L. Agate, S. Mazzeo, G. Materazzi, S. Sellari-Franceschini, A. Ribechini, L. Torregrossa, F. Basolo, P. Vitti, R. Elisei, Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13(11), 644\u2013660 (2017). https:\/\/doi.org\/10.1038\/nrendo.2017.76","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"2425_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ecl.2018.10.010","volume":"48","author":"AV Chintakuntlawar","year":"2019","unstructured":"A.V. Chintakuntlawar, R.L. Foote, J.L. Kasperbauer, K.C. Bible, Diagnosis and management of anaplastic thyroid cancer. Endocrinol. Metab. Clin. North Am. 48(1), 269\u2013284 (2019). https:\/\/doi.org\/10.1016\/j.ecl.2018.10.010","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"6","key":"2425_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"R.C. Smallridge, J.A. Copland, Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin. Oncol. (R. Coll. Radiol.) 22(6), 486\u2013497 (2010). https:\/\/doi.org\/10.1016\/j.clon.2010.03.013","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"8","key":"2425_CR4","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1210\/jc.2012-1314","volume":"97","author":"RC Smallridge","year":"2012","unstructured":"R.C. Smallridge, Approach to the patient with anaplastic thyroid carcinoma. J. Clin. Endocrinol. Metab. 97(8), 2566\u20132572 (2012). https:\/\/doi.org\/10.1210\/jc.2012-1314","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"2425_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/COC.0b013e31816a61f3","volume":"31","author":"J Chen","year":"2008","unstructured":"J. Chen, J.D. Tward, D.C. Shrieve, Y.J. Hitchcock, Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am. J. Clin. Oncol. 31(5), 460\u2013464 (2008). https:\/\/doi.org\/10.1097\/COC.0b013e31816a61f3","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"2425_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717x-9-90","volume":"9","author":"AK Dumke","year":"2014","unstructured":"A.K. Dumke, T. Pelz, D. Vordermark, Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat. Oncol. 9(1), 90 (2014). https:\/\/doi.org\/10.1186\/1748-717x-9-90","journal-title":"Radiat. Oncol."},{"key":"2425_CR7","doi-asserted-by":"publisher","unstructured":"K. Shimaoka, D.A. Schoenfeld, W.D. DeWys, R.H. Creech, R. DeConti, A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56(9), 2155\u20132160 (1985). https:\/\/doi.org\/10.1002\/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e","DOI":"10.1002\/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e"},{"issue":"7","key":"2425_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/thy.2000.10.587","volume":"10","author":"KB Ain","year":"2000","unstructured":"K.B. Ain, M.J. Egorin, P.A. DeSimone, Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10(7), 587\u2013594 (2000). https:\/\/doi.org\/10.1089\/thy.2000.10.587","journal-title":"Thyroid"},{"issue":"2","key":"2425_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1089\/thy.2013.0078","volume":"24","author":"JA Sosa","year":"2014","unstructured":"J.A. Sosa, R. Elisei, B. Jarzab, J. Balkissoon, S.P. Lu, C. Bal, S. Marur, A. Gramza, R.B. Yosef, B. Gitlitz, B.R. Haugen, F. Ondrey, C. Lu, S.M. Karandikar, F. Khuri, L. Licitra, S.C. Remick, Randomized safety and efficacy study of fosbretabulin with paclitaxel\/carboplatin against anaplastic thyroid carcinoma. Thyroid 24(2), 232\u2013240 (2014). https:\/\/doi.org\/10.1089\/thy.2013.0078","journal-title":"Thyroid"},{"key":"2425_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"M. Tahara, N. Kiyota, T. Yamazaki, N. Chayahara, K. Nakano, L. Inagaki, K. Toda, T. Enokida, H. Minami, Y. Imamura, T. Sasaki, T. Suzuki, K. Fujino, C.E. Dutcus, S. Takahashi, Lenvatinib for anaplastic thyroid cancer. Front Oncol 7, 25 (2017). https:\/\/doi.org\/10.3389\/fonc.2017.00025","journal-title":"Front Oncol"},{"issue":"1","key":"2425_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000457831","volume":"10","author":"T Fukuhara","year":"2017","unstructured":"T. Fukuhara, R. Donishi, S. Koyama, N. Miyake, E. Matsuda, K. Fujiwara, H. Kitano, H. Takeuchi, Significant amelioration of tracheal stenosis following lenvatinib in a patient who has anaplastic thyroid carcinoma with bronchomediastinal infiltration: a case report. Case Rep. Oncol 10(1), 175\u2013181 (2017). https:\/\/doi.org\/10.1159\/000457831","journal-title":"Case Rep. Oncol"},{"issue":"3","key":"2425_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000485972","volume":"7","author":"S Koyama","year":"2018","unstructured":"S. Koyama, N. Miyake, K. Fujiwara, T. Morisaki, T. Fukuhara, H. Kitano, H. Takeuchi, Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction. Eur. Thyroid J. 7(3), 139\u2013144 (2018). https:\/\/doi.org\/10.1159\/000485972","journal-title":"Eur. Thyroid J."},{"issue":"1.2","key":"2425_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2739\/kurumemedj.MS6406","volume":"64","author":"JI Ohkubo","year":"2018","unstructured":"J.I. Ohkubo, A. Takahashi, S. Ikezaki, F. Takenaga, Y. Ohkubo, H. Suzuki, Anaplastic thyroid carcinoma treated with Lenvatinib. Kurume Med. J. 64(1.2), 29\u201333 (2018). https:\/\/doi.org\/10.2739\/kurumemedj.MS6406","journal-title":"Kurume Med. J."},{"key":"2425_CR14","doi-asserted-by":"publisher","unstructured":"K. Oishi, D. Takabatake, Y. Shibuya, Efficacy of lenvatinib in a patient with anaplastic thyroid cancer. Endocrinol. Diabetes Metab. Case Rep. 2017 (2017). https:\/\/doi.org\/10.1530\/edm-16-0136","DOI":"10.1530\/edm-16-0136"},{"issue":"7","key":"2425_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621\u2013630 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2425_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian, S.G. Gwyther, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92(3), 205\u2013216 (2000). https:\/\/doi.org\/10.1093\/jnci\/92.3.205","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"2425_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10637-014-0181-7","volume":"33","author":"AC Dubbelman","year":"2015","unstructured":"A.C. Dubbelman, H. Rosing, C. Nijenhuis, A.D. Huitema, M. Mergui-Roelvink, A. Gupta, D. Verbel, G. Thompson, R. Shumaker, J.H. Schellens, J.H. Beijnen, Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest. New Drugs 33(1), 233\u2013240 (2015). https:\/\/doi.org\/10.1007\/s10637-014-0181-7","journal-title":"Invest. New Drugs"},{"issue":"8","key":"2425_CR18","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/1078-0432.Ccr-10-2638","volume":"17","author":"K Yamada","year":"2011","unstructured":"K. Yamada, N. Yamamoto, Y. Yamada, H. Nokihara, Y. Fujiwara, T. Hirata, F. Koizumi, K. Nishio, N. Koyama, T. Tamura, Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin. Cancer Res. 17(8), 2528\u20132537 (2011). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2638","journal-title":"Clin. Cancer Res."},{"key":"2425_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","volume":"106","author":"M Tahara","year":"2019","unstructured":"M. Tahara, M.S. Brose, L.J. Wirth, T. Suzuki, H. Miyagishi, K. Fujino, C.E. Dutcus, A. Gianoukakis, Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur. J. Cancer 106, 61\u201368 (2019). https:\/\/doi.org\/10.1016\/j.ejca.2018.10.002","journal-title":"Eur. J. Cancer"},{"key":"2425_CR20","doi-asserted-by":"publisher","unstructured":"E. Song, M. Kim, E.Y. Kim, B.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, K.B. Kim, Y.K. Shong, M.J. Jeon, D.J. Lim, Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid (2020). https:\/\/doi.org\/10.1089\/thy.2019.0476","DOI":"10.1089\/thy.2019.0476"},{"issue":"1","key":"2425_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"P.C. Iyer, R. Dadu, R. Ferrarotto, N.L. Busaidy, M.A. Habra, M. Zafereo, N. Gross, K.R. Hess, M. Gule-Monroe, M.D. Williams, M.E. Cabanillas, Real-world experience with targeted therapy for the treatment of anaplastic thyroid Carcinoma. Thyroid 28(1), 79\u201387 (2018). https:\/\/doi.org\/10.1089\/thy.2017.0285","journal-title":"Thyroid"},{"issue":"7","key":"2425_CR22","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.20936","volume":"103","author":"E Kebebew","year":"2005","unstructured":"E. Kebebew, F.S. Greenspan, O.H. Clark, K.A. Woeber, A. McMillan, Anaplastic thyroid carcinoma. Treat. Out. Prog. Factors. Cancer 103(7), 1330\u20131335 (2005). https:\/\/doi.org\/10.1002\/cncr.20936","journal-title":"Treat. Out. Prog. Factors. Cancer"},{"issue":"1","key":"2425_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/jco.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg, J.Y. Cho, J.H.M. Schellens, J.C. Soria, P.Y. Wen, C. Zielinski, M.E. Cabanillas, G. Urbanowitz, B. Mookerjee, D. Wang, F. Rangwala, B. Keam, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J. Clin. Oncol. 36(1), 7\u201313 (2018). https:\/\/doi.org\/10.1200\/jco.2017.73.6785","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"2425_CR24","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1089\/thy.2019.0133","volume":"29","author":"JR Wang","year":"2019","unstructured":"J.R. Wang, M.E. Zafereo, R. Dadu, R. Ferrarotto, N.L. Busaidy, C. Lu, S. Ahmed, M.K. Gule-Monroe, M.D. Williams, E.M. Sturgis, R.P. Goepfert, N.D. Gross, S.Y. Lai, G.B. Gunn, J. Phan, D.I. Rosenthal, C.D. Fuller, W.H. Morrison, P. Iyer, M.E. Cabanillas, Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29(8), 1036\u20131043 (2019). https:\/\/doi.org\/10.1089\/thy.2019.0133","journal-title":"Thyroid"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02425-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02425-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T23:54:00Z","timestamp":1627516440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02425-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2425"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02425-y","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,29]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study protocol was reviewed and approved by the Institutional Review Board of each participating institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}